STOCKWATCH: Vertex's almost incomplete disclosure
This article was originally published in Scrip
Executive Summary
That infamous letter from three members of the US House of Representatives to the CEO of Gilead Sciences (which we hold), questioning the price of Sovaldi (sofosbuvir) in the treatment of hepatitis C virus (HCV) infection, has come to be known as the catalyst that started the great biotech sell-off of 2014 (scripintelligence.com, 25 March 2014). The tempo of the debate on US drug pricing was further accelerated when the CEO of the largest pharmacy benefit manager, Express Scripts, warned that the price of Sovaldi was unsustainable and called for its clients to stop using it when competitor drugs gain approval.